Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$11.31
-0.6%
$12.53
$11.25
▼
$17.31
$238.34M0.8175,981 shs81,785 shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$1.87
-13.8%
$2.63
$1.66
▼
$3.94
$288.62M2.082.24 million shs2.11 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%-1.98%+0.53%-18.77%-30.35%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
0.00%-15.56%-7.66%-23.59%-16.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$11.31
-0.6%
$12.53
$11.25
▼
$17.31
$238.34M0.8175,981 shs81,785 shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$1.87
-13.8%
$2.63
$1.66
▼
$3.94
$288.62M2.082.24 million shs2.11 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%-1.98%+0.53%-18.77%-30.35%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
0.00%-15.56%-7.66%-23.59%-16.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.33
Sell$13.0014.94% Upside
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.71
Moderate Buy$5.83211.94% Upside

Current Analyst Ratings Breakdown

Latest AMRN and EDIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/4/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Reiterated RatingSell (D-)
11/3/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
DowngradeStrong-Buy ➝ Hold
10/15/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Reiterated RatingSell (D-)
10/8/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
UpgradeEqual Weight ➝ Overweight$4.00 ➝ $6.00
10/5/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
UpgradeHold ➝ Strong-Buy
9/23/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
UpgradeNeutral ➝ Buy$5.00
8/21/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Initiated CoverageUnderweight$13.00
8/18/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Initiated CoverageBuy$6.00
8/17/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
DowngradeStrong-Buy ➝ Hold
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$176.11M1.35$0.36 per share31.53$22.07 per share0.51
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$40.52M7.12N/AN/A$0.28 per share6.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$38.80M-$0.96N/AN/AN/A-10.87%-0.52%-0.36%N/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$160.06M-$0.62N/AN/AN/A-144.95%-130.43%-36.45%N/A

Latest AMRN and EDIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.1853-$0.15+$0.0353-$0.15$4.46 million$10.37 million
10/28/2026Q3 2026
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.0972$0.01+$0.1072$0.01$43.76 million$39.55 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.50
2.59
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
2.82
2.82

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
4.21%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
8021.07 million20.19 millionOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
87154.34 million149.56 millionOptionable

Recent News About These Companies

Editas Medicine (NASDAQ:EDIT) EVP Sells 7,814 Shares of Stock
FY2026 EPS Estimate for Editas Medicine Increased by Analyst
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
FY2026 EPS Forecast for Editas Medicine Raised by Analyst
EDITAS MEDICINE, INC. Q3 Loss Decreases
Editas: Q3 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$11.31 -0.07 (-0.62%)
Closing price 04:00 PM Eastern
Extended Trading
$11.31 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$1.87 -0.30 (-13.82%)
Closing price 04:00 PM Eastern
Extended Trading
$1.92 +0.04 (+2.41%)
As of 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.